This MAb recognizes human 17-26kDa protein, which is identified as cytokine TNF-α (Tumor Necrosis Factor-alpha). Monomeric human TNF-α is a 157 amino acid protein (non-glycosylated) with a reported molecular weight of 17 kDa and can be expressed as a free molecule, also TNF-α is generated as a precursor form called transmembrane TNF-α can be expressed as a cell surface type II polypeptide consisting of 233 amino acid residues molecular weight 26 kDa. TNF-α is an important cell-signaling component of the immune system. It is a protein secreted by LPS stimulated macrophages, and causes tumor necrosis when injected into tumor bearing mice. TNF-α is currently being evaluated in treatment of certain cancers and AIDS Related Complex.
Recognizes a 47-55kDa-tumor suppressor protein, identified as Wilm's Tumor (WT1) protein. The antibody reacts with all isoforms of the full-length WT1 and also identifies WT1 lacking exon 2-encoded amino acids, frequently found in subsets of sporadic Wilms tumors. WT1, a sporadic and familial pediatric kidney tumor, is genetically heterogeneous. Wilms tumor is associated with mutations of WT1, a zinc-finger transcription factor that is essential for the development of the metanephric kidney and the urogenital system. The WT1 gene is normally expressed in fetal kidney and mesothelium, and its expression has been suggested as a marker for Wilms tumor and mesothelioma. WT1 protein has been identified in proliferative mesothelial cells, malignant mesothelioma, ovarian carcinoma, gonadoblastoma, nephroblastoma, and desmoplastic small round cell tumor. Lung adenocarcinomas rarely stain positive with this antibody. WT1 protein expression in mesothelial cells has become a reliable marker for the diagnosis of mesotheliomas.
Product category: Tumor markers, Diagnostic agents / kits for tumour marker determination, Reagents for tumour marker determination
Wilms Tumor 1 Protein (WT1)
Wilms tumor-1 (WT-1), is a gene involved in the induction of Wilms tumor, a pediatric renal malignancy. Wilms tumor is associated with mutations of WT1, a zinc-finger transcription factor that is essential for the development of the metanephric kidney and the urogenital system. The WT1 gene is normally expressed in fetal kidney and mesothelium, and its expression has been suggested as a marker for Wilms tumor and mesothelioma.
Since 1994, Diagnostic BioSystems Inc. is committed to enhancing immunohistochemistry results by providing innovative anatomic pathology reagents and systems to improve the practice of pathology. Since the inception, our prime focus has been to provide high quality products and exceptional customer service and support.
Diagnostic BioSystems provides cutting-edge in-vitro diagnostics to the anatomic pathology and histology market through direct sales in the domestic market and through international distributors to over 60 countries worldwide. Our product portfolio includes high quality primary and FITC antibodies, autostainer, chromogens, detection kits and a wide range of ancillaries.
Diagnostic BioSystems is an ISO 9001:2008 certified cGMP compliant, medical device manufacturer.